METHODS AND TREATMENTS FOR ERECTILE DYSFUNCTION
In one embodiment, a pharmaceutical composition for treatment of erectile dysfunction is provided including a therapeutically effective amount of a phosphodiesterase-5 (PDE-5) inhibitor, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one of tetrahydrocannabinol (THC), and cannabidiol (CBD).
1 . A pharmaceutical composition for treatment of erectile dysfunction, comprising:
a therapeutically effective amount of a phosphodiesterase-5 (PDE-5) inhibitor, or a pharmaceutically acceptable salt thereof; and
a therapeutically effective amount of at least one of:
tetrahydrocannabinol (THC), and
cannabidiol (CBD).
2 . The pharmaceutical composition of claim 1 , wherein the PDE- 5 inhibitor comprises sildenafil and/or tadalafil.
3 . The pharmaceutical composition of claim 1 , wherein the CBD is extracted from cannabis indica.
4 . The pharmaceutical composition of claim 1 , comprising both THC and CBD, wherein the THC and CBD are provided in a 5:2 ratio (THC:CBD).
5 . The pharmaceutical composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
6 . The pharmaceutical composition of claim 1 , comprising 0.01 mg-150 mg of the PDE-5 inhibitor.
7 . The pharmaceutical composition of claim 6 , comprising 0.1 mg-100 mg of the PDE-5 inhibitor.
8 . The pharmaceutical composition of claim 1 , comprising 0.01 mg-150 mg of THC.
9 . The pharmaceutical composition of claim 8 , comprising 0.1 mg-100 mg of THC.
10 . The pharmaceutical composition of claim 1 , comprising 0.01 mg-1500 mg of CBD.
11 . The pharmaceutical composition of claim 10 , comprising 0.1-1000 mg of CBD.
12 . The pharmaceutical composition of claim 1 , wherein PDE-5 inhibitor comprises sildenafil and/or tadalafil.
13 . A pharmaceutical composition comprising a phosphodiesterase-5 (PDE-5) inhibitor and THC or CBD for the treatment of erectile dysfunction.
14 . A method of eliciting or prolonging an erection in a patient, or both, comprising:
administering to the patient a therapeutically effective amount of a phosphodiesterase-5 (PDE-5) inhibitor, or a pharmaceutically acceptable salt thereof; and
co-administering a therapeutically effective amount of at least one of:
tetrahydrocannabinol (THC), and
cannabidiol (CBD).
15 . The method of claim 14 , wherein the PDE-5 inhibitor comprises sildenafil and/or tadalafil.
16 . The method of claim 14 , further comprising wherein both THC and CBD are administered to the patient.
17 . The method of claim 14 , wherein the THC and CBD are administered to the patient in a 5:2 ratio (THC:CBD).
18 . (canceled)
19 . The method of claim 14 , wherein a duration of erection comprises at least one hour.
20 . The method of claim 14 , wherein a duration of erection comprises at least three hours.
21 . The method of claim 14 , wherein the PDE-5 inhibitor is administered prior to administration of the THC and/or the CBD.